AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma: final results of an open-label, randomized, multicenter phase II trial.

Autor: Sasse, Stephanie^1,2 (AUTHOR) stephanie.sasse1@uk-koeln.de, Bröckelmann, Paul Jan^1,3 (AUTHOR), Momotow, Jesko^1,3 (AUTHOR), Plütschow, Annette^1,3 (AUTHOR), Hüttmann, Andreas⁴ (AUTHOR), Basara, Nadezda⁵ (AUTHOR), Koenecke, Christian⁶ (AUTHOR), Martin, Sonja⁷ (AUTHOR), Bentz, Martin⁸ (AUTHOR), Grosse-Thie, Christina⁹ (AUTHOR), Thorspecken, Sven¹⁰ (AUTHOR), de Wit, Maike¹¹ (AUTHOR), Kobe, Carsten^1,12 (AUTHOR), Dietlein, Markus^1,12 (AUTHOR), Tresckow, Bastian von^1,4 (AUTHOR), Fuchs, Michael^1,3 (AUTHOR), Borchmann, Peter^1,3 (AUTHOR), Engert, Andreas^1,3 (AUTHOR)

Publikováno v: Leukemia & Lymphoma. Aug2022, Vol. 63 Issue 8, p1871-1878. 8p.